News

Academy’s 2023 program taking place in San Francisco.

Polish researchers found positive bacterial cultures in premature infants correlated with severe retinopathy of prematurity (ROP), suggesting a potential prognostic marker for early ROP development.

World Sight Day on October 12 highlights the vital role of eye care in workplaces. The International Agency for the Prevention of Blindness urges employers to prioritize eye health, aiming to enhance well-being, safety, and productivity.

The authors of a case series say silicone oil droplets from silicone used to lubricate the McKesson syringes is the most likely cause of the droplets presumed to cause the floaters.

According to the company, a change from base line best corrected visual acuity based on an average at week 44, 48 and 52 serves as the primary endpoint.

The 23rd annual EURETINA Congress took place in Amsterdam, the Netherlands. We spoke with Arshad M. Khanani, MD, MA, FASRS, who provided an overview of his presentation, "Emerging therapies for exudative AMD."

G6501 is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).

The company announced preliminary US net revenues of about $74 million for the injection, approved by the FDA earlier this year.

This milestone was announced by Clearside Biomedical, Inc., Arctic Vision's partner. ARCATUS, also known as XIPERE®, utilizes a revolutionary suprachoroidal delivery platform, offering new hope to patients in China suffering from this vision-threatening condition.

Few injections lowers treatment burden and maintains safety profile.

The new range of pure and premixed gases are intended for medium-term use in retinal surgery.

Ali Erginay, MD, of Lariboisière Hospital in Paris, France, discusses his EURETINA presentation, "Introducing optomap® Ultra-widefield Colour Red-Green-Blue Multimodal Imaging."

We spoke with Michael Singer, MD who provided an overview of his presentation and his work with Nanoscope Therapeutics, "MCO-010 Optogenetic Therapy to Treat Stargardt Disease: Safety and Efficacy through Week 48 in the Phase 2a STARLIGHT Clinical Trial."

The collaboration will drive an effort to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vision loss for people with serious eye diseases.

A subgroup analysis of the phase 3 PULSAR Trial showed robust increases in the best-corrected visual acuity (BCVA) compared with baseline at week 48.

Our team spoke to David Almeida, MD, PhD, MBA about his EURETINA presentation titled, The Real-World Efficacy and Safety of Faricimab in Neovascular AMD: The TRUCKEE Study.

Case 1 highlights the potential for this treatment for patients with dry AMD with noted letter gains

Robyn Guymer, MBBS, PhD, Deputy Director, Centre for Eye Research Australia, and Professor of Surgery (Ophthalmology), University of Melbourne, Australia, discussed the study findings at the 23rd annual Euretina Congress, Amsterdam.

Our team spoke to Varun Chaudhary, MD, about his EURETINA presentation, titled "Systematic Review and Metanalysis in Macular Hole RCTs – Posturing after Macular Hole Surgery."

An increase in sexually transmitted infections may be causing an increase in number of eye infections.

Researchers have developed a robotic system that automatically positions examination sensors to scan human eyes.

Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."

Altris also has advanced AI models to enable vendor-neutral retina layers segmentation as well as detection and visualization of more than 70 retina conditions such as dry and wet age-related macular degeneration, geographic atrophy, diabetic retinopathy, diabetic macular edema and central retinal vein occlusion.

Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."

Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."

The company announced its previously announced agreement to divest its late-stage ophthalmic assets to Laboratoires Théa S.A.S. has been terminated.

The specialty pharmaceutical research company’s new retinal vascular dysfunction model can have an impact on the research and development of new drugs for retinal vascular diseases.

Kriya is developing a one-time gene therapy designed to block complement C3 and C5, which are clinically validated substrates targeted by FDA approved therapies, to delay the progression of geographic atrophy.